ArriVent BioPharma experienced a significant market decline on Tuesday, with shares closing down approximately 47% following the announcement of a failed Phase 3 clinical trial. The company reported that firmonertinib, a treatment for non-small cell lung cancer, did not achieve its primary goal in the study.

This development has drawn attention to the broader risks associated with the strategy of licensing drugs from Chinese biotech firms for global distribution. Analysts suggest that the failure underscores the complexities and regulatory hurdles involved in taking Chinese-developed therapies through international clinical trials. The drug was originally developed by Shanghai Allist Pharmaceuticals, and the trial results represent a major setback for ArriVent’s current pipeline. While the company has not yet detailed its next steps, the market reaction reflects investor concern regarding the viability of this specific licensing model and the potential for future delays in bringing these treatments to Western markets.